Harvard Bioscience (HBIO) 10-K 12 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 05, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Central Index Key	0001123494
Entity Registrant Name	HARVARD BIOSCIENCE INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	001-33957
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 116,000,000
Entity Common Stock, Shares Outstanding		39,825,533

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 8,317	$ 8,335
Accounts receivable, net	17,766	20,704
Inventories	22,262	22,061
Other current assets	3,355	2,472
Total current assets	51,700	53,572
Property, plant and equipment, net	3,960	4,776
Operating lease right-of-use assets	7,761	8,463
Goodwill	58,590	57,381
Intangible assets, net	33,151	38,405
Other long-term assets	1,092	2,273
Total assets	156,254	164,870
Current liabilities:
Current portion of long-term debt	1,721	6,900
Current portion of operating lease liabilities	2,111	2,424
Accounts payable	5,972	5,339
Deferred revenue	3,771	3,949
Other current liabilities	7,478	6,700
Total current liabilities	21,053	25,312
Long-term debt	46,286	46,917
Deferred tax liability	1,899	1,974
Operating lease liabilities	7,481	8,224
Other long-term liabilities	2,854	749
Total liabilities	79,573	83,176
Commitments and contingencies - Note 15
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 47,152,587 and 45,933,715 shares issued and 39,407,080 and 38,188,208 shares outstanding, respectively	444	438
Additional paid-in-capital	232,357	229,189
Accumulated deficit	(132,386)	(124,576)
Accumulated other comprehensive loss	(13,066)	(12,689)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	76,681	81,694
Total liabilities and stockholders' equity	$ 156,254	$ 164,870

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	47,152,587	45,933,715
Common stock, shares outstanding (in shares)	39,407,080	38,188,208
Treasury stock, common shares (in shares)	7,745,507	7,745,507

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 102,100	$ 116,176
Cost of revenues	44,059	51,854
Gross margin	58,041	64,322
Operating expenses:
Sales and marketing expenses	19,916	23,264
General and administrative expenses	23,509	22,760
Research and development expenses	8,685	10,715
Amortization of intangible assets	5,710	5,746
Impairment charges	0	1,460
Total operating expenses	57,820	63,945
Operating income	221	377
Other expense:
Interest expense	(4,831)	(5,410)
Debt extinguishment and related costs	(1,876)	0
Other expense, net	(806)	(469)
Total other expense	(7,513)	(5,879)
Loss before income taxes	(7,292)	(5,502)
Income tax expense (benefit)	518	(815)
Net loss	$ (7,810)	$ (4,687)
Loss per share:
Basic and diluted loss per share (in dollars per share)	$ (0.20)	$ (0.12)
Weighted-average common shares:
Basic and diluted (in shares)	38,640	37,814

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (7,810)	$ (4,687)
Other comprehensive income (loss):
Foreign currency translation adjustments	1,700	(543)
Derivatives qualifying as hedges, net of tax:
Loss on derivative instruments designated and qualifying as cash flow hedges	(206)	(572)
Amounts reclassified from accumulated other comprehensive loss to net loss	809	139
Derivatives qualifying as hedges, net of tax	603	(433)
Defined benefit pension plans, net of tax:
Net (loss) gain	(2,785)	1,258
Amounts reclassified from accumulated other comprehensive loss to net loss	105	561
Defined benefit pension plans, net of tax	(2,680)	1,819
Other comprehensive (loss) income	(377)	843
Comprehensive loss	$ (8,187)	$ (3,844)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	45,124,000
Balance at Dec. 31, 2018	$ 436	$ 226,377	$ (119,889)	$ (13,532)	$ (10,668)	$ 82,724
Stock option exercises (in shares)	4,000					3,750
Stock option exercises	$ 0	11	0	0	0	$ 11
Shares issued under stock purchase plan (in shares)	191,000					190,642
Shares issued under stock purchase plan	$ 2	323	0	0	0	$ 325
Vesting of restricted stock units (in shares)	818,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(203,000)
Shares withheld for taxes	$ 0	(556)	0	0	0	(556)
Stock compensation expense	0	3,034	0	0	0	3,034
Net loss	0	0	(4,687)	0	0	(4,687)
Other comprehensive income	$ 0	0	0	843	0	843
Balance (in shares) at Dec. 31, 2019	45,934,000
Balance at Dec. 31, 2019	$ 438	229,189	(124,576)	(12,689)	(10,668)	$ 81,694
Stock option exercises (in shares)	254,000					253,853
Stock option exercises	$ 4	318	0	0	0	$ 322
Shares issued under stock purchase plan (in shares)	126,000					126,255
Shares issued under stock purchase plan	$ 2	345	0	0	0	$ 347
Vesting of restricted stock units (in shares)	1,171,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(332,000)
Shares withheld for taxes	$ 0	(1,142)	0	0	0	(1,142)
Stock compensation expense	0	3,647	0	0	0	3,647
Net loss	0	0	(7,810)	0	0	(7,810)
Other comprehensive income	$ 0	0	0	(377)	0	(377)
Balance (in shares) at Dec. 31, 2020	47,153,000
Balance at Dec. 31, 2020	$ 444	$ 232,357	$ (132,386)	$ (13,066)	$ (10,668)	$ 76,681

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (7,810)	$ (4,687)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	1,922	1,987
Amortization of intangible assets	5,710	5,746
Amortization of deferred financing costs	393	385
Write-off of unamortized deferred financing costs	787	0
Debt extinguishment cost	599	0
Stock-based compensation expense	3,647	3,034
Impairment charges	0	1,460
Provision for allowance for doubtful accounts	17	288
Deferred income taxes	(143)	(398)
Other	103	188
Changes in operating assets and liabilities:
Accounts receivable	3,105	468
Inventories	413	3,260
Other assets	293	165
Accounts payable	511	(2,048)
Deferred revenue	(184)	121
Other liabilities	(32)	(1,924)
Net cash provided by operating activities	9,331	8,045
Cash flows from investing activities:
Additions to property, plant and equipment	(1,152)	(1,216)
Disposition of business	0	1,002
Other	(250)	(15)
Net cash used in investing activities	(1,402)	(229)
Cash flows from financing activities:
Proceeds from issuance of debt	61,315	4,300
Repayments of debt	(66,912)	(11,703)
Debt issuance cost	(1,298)	0
Debt extinguishment cost	(599)	0
Taxes paid for net share settlement of equity awards	(473)	(221)
Net cash used in financing activities	(7,967)	(7,624)
Effect of exchange rate changes on cash	20	(30)
(Decrease) Increase in cash and cash equivalents	(18)	162
Cash and cash equivalents at beginning of year	8,335	8,173
Cash and cash equivalents at end of year	8,317	8,335
Supplemental disclosures of cash flow information:
Cash paid for interest	4,881	5,496
Cash paid for income taxes, net of refunds	$ 416	$ 374

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Organization Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe and China, the Company has sales through a combination of direct and distribution channels to customers around the world. Risks and Uncertainties On March 11, 2020, 19 19 19 As a result of these market and economic conditions, the Company performed an analysis for potential impairment indicators of its intangible and other long-lived assets in accordance with the guidelines set forth in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350, 360, December 31, 2020, no 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies (a) Principles of Consolidation The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. (b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory excess and obsolescence, income tax and reserves for bad debts. In addition, certain estimates are required in order to determine the value of assets and liabilities associated with acquisitions, as well as the Company’s defined benefit pension obligations. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates. (c) Cash and Cash Equivalents The Company considers all highly liquid instruments with original maturities of three may not not (d) Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on considering factors such as historical experience, credit quality, known troubled accounts, historical experience, factors that may (e) Inventories The Company values its inventories at the lower of the actual cost to purchase ( first first (f) Property, Plant and Equipment Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10 Property and equipment held under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. (g) Leases The Company accounts for its leases in accordance with ASC 842 12 not The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not (h) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not 50% (i) Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive (loss) income (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net (loss) income. (j) Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive. (k) Comprehensive (Loss) Income In accordance with ASC 220, (l) Revenue Recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, including the United States National Institutes of Health (NIH) and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer (OEM) customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may not Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may may, no may may not 606. Service revenues consist of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not one one For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to any and all remaining performance obligations are generally expected to be recognized in one one Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not not The Company’s payment terms are generally from zero sixty Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not Disaggregation of revenue Refer to Note 13 16 (m) Valuation of Identifiable Intangible Assets Acquired in Business Combinations The determination of the fair value of intangible assets, which represents a significant portion of the purchase price in the Company’s acquisitions, requires the use of significant judgment with regard to (i) the fair value; and (ii) whether such intangibles are amortizable or not (n) Goodwill and Other Intangible Assets Goodwill and unamortizable intangible assets acquired in a business combination and determined to have an indefinite useful life are not 350, For the purpose of its goodwill analysis, the Company has one fourth not December 31, 2020, none The Company evaluates indefinite-lived intangible assets for impairment annually and when events occur, or circumstances change that may 4 (o) Impairment of Long-Lived Assets The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with ASC 360, may not December 31, 2020, none (p) Derivatives The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not not The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. The Company discontinues hedge accounting prospectively when it determines that the derivative is no not In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not (q) Fair Value of Financial Instruments The carrying values of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity. Financial reporting standards define a fair value hierarchy that consists of three § Level 1 § Level 2 not § Level 3 (r) Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of ASC 718, 2000 Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model or Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables. These variables include, but are not The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant and are recorded as compensation expense on a straight-line basis over the applicable service period, which ranges from one four Stock-based compensation expense recognized under ASC 718 December 31, 2020 2019 10 (s) Recent Accounting Pronouncements Accounting Pronouncements to be Adopted In September 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 Instruments (ASU 2016 13 may 2016 13 2016 13 December 15, 2022, 2016 13 In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 2019 12 2019 12 January 1, 2021. not

Note 3 - Accumulated Other Comp

Note 3 - Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	3. Accumulated Other Comprehensive Loss Changes in the components of accumulated other comprehensive loss, net of tax, for the years ended December 31, 2020 2019, Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2018 $ (12,630 ) $ (170 ) $ (732 ) $ (13,532 ) Other comprehensive income (loss) before reclassifications (543 ) (572 ) 1,258 143 Amounts reclassified from AOCI - 139 561 700 Net other comprehensive (loss) income (543 ) (433 ) 1,819 843 Balance at December 31, 2019 $ (13,173 ) $ (603 ) $ 1,087 $ (12,689 ) Other comprehensive income (loss) before reclassifications 1,700 (206 ) (2,785 ) (1,291 ) Amounts reclassified from AOCI - 809 105 914 Net other comprehensive (loss) income 1,700 603 (2,680 ) (377 ) Balance at December 31, 2020 $ (11,473 ) $ - $ (1,593 ) $ (13,066 ) The amounts reclassified out of accumulated other comprehensive (loss) income are as follows: Affected line item in the Year Ended December 31, (in thousands) Statements of Operations 2020 2019 Amounts Reclassified From AOCI Derivatives qualifying as hedges Realized loss on derivatives qualifying as hedges Interest expense, net $ 319 $ 139 Realized loss on derivatives qualifying as hedges Debt extinguishment and related costs 490 - Income tax Income tax (benefit) expense - - 809 139 Defined benefit pension plans Amortization of net losses included in net periodic pension costs General and administrative expenses 105 561 Income tax Income tax (benefit) expense - - 105 561 Total reclassifications $ 914 $ 700

Note 4 - Goodwill and Intangibl

Note 4 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	4. Goodwill and Intangible Assets Goodwill The change in the carrying amount of goodwill for the year ended December 31, 2020 2019 December 31, (in thousands) 2020 2019 Balance at beginning of year $ 57,381 $ 57,304 Effect of change in currency translation 1,209 77 Balance at end of year $ 58,590 $ 57,381 December 31, 2020 2019 Weighted (in thousands) Amortizable intangible assets: Average Life* (Years) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Distribution agreements/customer relationships 8.8 $ 18,237 $ (7,746 ) $ 10,491 $ 17,891 $ (6,340 ) $ 11,551 Existing technology 5.2 38,761 (20,674 ) 18,087 41,222 (19,698 ) 21,524 Trade names and patents 5.4 8,681 (4,362 ) 4,319 7,910 (3,715 ) 4,195 Total amortizable intangible assets $ 65,679 $ (32,782 ) $ 32,897 $ 67,023 $ (29,753 ) $ 37,270 Indefinite-lived intangible assets: 254 1,135 Total intangible assets $ 33,151 $ 38,405 * Weighted average life as of December 31, 2020. During the year ended December 31, 2020, 2020 During the year ended December 31, 2019, Intangible asset amortization expense was $5.7 million for each of the years ended December 31, 2020 2019, five December 31, 2020 Amortization Year Ending December 31, Expense (in thousands) 2021 $ 5,774 2022 5,740 2023 5,627 2024 5,318 2025 4,204 Thereafter 6,234 Total $ 32,897

Note 5 - Balance Sheet Informat

Note 5 - Balance Sheet Information	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	5. Balance Sheet Information The following tables provide details of selected balance sheet items as of the periods indicated: Inventories: December 31, (in thousands) 2020 2019 Finished goods $ 4,938 $ 5,561 Work in process 3,513 3,153 Raw materials 13,811 13,347 Total $ 22,262 $ 22,061 Other Current Liabilities: December 31, (in thousands) 2020 2019 Compensation $ 3,715 2,554 Professional fees 432 395 Warranty costs 185 252 Customer related costs 1,093 963 Interest 46 425 Accrued income taxes 286 609 Other 1,721 1,502 Total $ 7,478 $ 6,700 Property, Plant and Equipment: December 31, (in thousands) 2020 2019 Machinery and equipment $ 7,450 $ 7,198 Computer equipment and software 9,114 8,954 Leasehold improvements 2,540 2,151 Furniture and fixtures 1,353 1,321 Automobiles 100 92 20,557 19,716 Less: accumulated depreciation (16,597 ) (14,940 ) Property, plant and equipment, net $ 3,960 $ 4,776

Note 6 - Restructuring and Othe

Note 6 - Restructuring and Other Exit Costs	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	6. Restructuring and Other Exit Costs On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes restructuring-type activities from time to time to transform its business. During 2019, first 2021. The following table summarizes the activity for accrued restructuring liability for the years ended December 31, 2020 2019: Cost of Severance (in thousands) Revenue Costs Impairment Other Total Restructuring and other exit costs $ 235 $ 530 $ 460 $ 129 $ 1,354 Non-cash charges (235 ) - (460 ) (10 ) (705 ) Cash payments - (166 ) - (115 ) (281 ) Balance at December 31, 2019 - 364 - 4 368 Restructuring and other exit costs - 1,625 - 408 2,033 Non-cash charges - - - (168 ) (168 ) Cash payments - (1,719 ) - (226 ) (1,945 ) Balance at December 31, 2020 $ - $ 270 $ - $ 18 $ 288 As of December 31, 2020, twelve During the year ended December 31, 2019, Restructuring costs of $2.0 million incurred during the year ended December 31, 2020, December 31, 2019,

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	7. Related Party Transactions In connection with the 2014 September 30, 2019, December 31, 2024. December 31, 2020 2019,

Note 8 - Employee Benefit Plans

Note 8 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Retirement Benefits [Text Block]	8. Employee Benefit Plans The Company sponsors profit sharing retirement plans for its U.S. employees, which includes employee savings plans established under Section 401 “401 401 401 December 31, 2020 2019, 401 The Company’s subsidiary in the United Kingdom, Biochrom Limited maintains contributory, defined benefit or defined contribution pension plans for substantially all of its employees. In 2014, 715 20 715 20 not The components of the Company’s net period benefit (credit) expense were as follows: Year Ended December 31, (in thousands) 2020 2019 Interest cost $ 391 $ 484 Expected return on plan assets (733 ) (761 ) Net amortization loss 105 336 Recognition of net loss due to settlements 22 228 Net periodic benefit (credit) cost $ (215 ) $ 287 The measurement date is December 31 December 31, 2020 2019 December 31, (in thousands) 2020 2019 Change in benefit obligation: Balance at beginning of year $ 20,027 $ 18,701 Interest cost 391 484 Actuarial loss 4,814 1,513 Settlements due to transfers paid (205 ) (871 ) Benefits paid (476 ) (447 ) Currency translation adjustment 968 647 Balance at end of year $ 25,519 $ 20,027 Changes in the actuarial loss disclosed above are primarily the result of changes in the discount rate and inflation assumptions due to underlying market conditions. December 31, (in thousands) 2020 2019 Change in fair value of plan assets: Balance at beginning of year $ 21,114 $ 17,819 Actual return on plan assets 1,690 3,172 Employer contributions 901 831 Settlement due to transfers paid (159 ) (931 ) Benefits paid (476 ) (447 ) Currency translation adjustment 856 670 Balance at end of year $ 23,926 $ 21,114 December 31, (in thousands) 2020 2019 Benefit obligation $ (25,519 ) $ (20,027 ) Fair value of plan asset 23,926 21,114 Net funded status $ (1,593 ) $ 1,087 The amounts recognized in the consolidated balance sheets consist of: December 31, (in thousands) 2020 2019 Other long term (liabilities) assets $ (1,593 ) $ 1,087 Deferred income taxes - - Accumulated other comprehensive loss $ (1,593 ) $ 1,087 The weighted average assumptions used in determining the net pension cost for these plans follows: Year Ended December 31, 2020 2019 Discount rate 1.4 % 2.02 % Expected return on assets 3.45 % 3.84 % The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations. The Company’s mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2020, 15 The fair value and asset allocations of the Company’s pension benefits as of December 31, 2020 2019 December 31, (in thousands) 2020 2019 Asset category: Equity securities $ 12,047 50 % $ 11,534 55 % Debt securities 4,605 19 % 3,919 19 % Liability driven investment funds 5,168 22 % 3,615 17 % Cash and cash equivalents 1,860 8 % 1,514 7 % Other 246 1 % 532 3 % Total $ 23,926 100 % $ 21,114 100 % Financial reporting standards define a fair value hierarchy that consists of three December 31, 2020 2019 December 31, (in thousands) 2020 2019 Quoted Prices in Active Markets for Identical Assets (Level 1) $ 1,860 $ 1,514 Significant Other Observable Inputs (Level 2) 22,066 19,600 Significant Other Unobservable Inputs (Level 3) - - Total $ 23,926 $ 21,114 Level 1 December 31, 2020. 2 not The Company expects to contribute at least $1.0 million to its pension plans during 2021. 2021, 2022, 2023, 2024 2025. five 2026—2030

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases The Company has noncancelable operating leases for office space, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030. The components of lease expense for the year ended December 31, 2020 2019 Year Ended December 31, (in thousands) 2020 2019 Operating lease cost $ 2,153 $ 2,084 Short term lease cost 175 245 Sublease income (183 ) (429 ) Total lease cost $ 2,145 $ 1,900 Supplemental cash flow information related to the Company’s operating leases was as follows: Year Ended December 31, (in thousands) 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: $ 2,717 $ 2,530 Right-of-use assets obtained in exchange for lease obligations: $ 455 $ 177 Supplemental balance sheet information related to the Company’s operating leases was as follows: December 31, (in thousands) 2020 2019 Operating lease right-of use assets $ 7,761 $ 8,463 Current portion, operating lease liabilities $ 2,111 $ 2,424 Operating lease liabilities, long term 7,481 8,224 Total operating lease liabilities $ 9,592 $ 10,648 Weighted average remaining lease term (in years) 7.4 8.1 Weighted average discount rate 9.3 % 9.2 % Future minimum lease payments for operating leases, with initial or remaining terms in excess of one December 31, 2020, (in thousands) Operating Leases 2021 $ 2,111 2022 2,018 2023 1,970 2024 1,715 2025 1,000 Thereafter 4,854 Total lease payments 13,668 Less interest (4,076 ) Total operating lease liabilities $ 9,592

Note 10 - Capital Stock and Sto

Note 10 - Capital Stock and Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Shareholders' Equity and Share-based Payments [Text Block]	10. Capital Stock and Stock-Based Compensation Preferred Stock The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may December 31, 2020, Employee Stock Purchase Plan Under the ESPP participating employees can authorize the Company to withhold a portion of their base pay during consecutive six six June 30 December 31. May 16, 2019, December 31, 2020 2019, December 31, 2020, 2000 Incentive Plan ) The stockholders of the Company have approved the Incentive Plan which authorizes the grant of stock options and stock-based awards to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. During 2020, 2020 December 31, 2020, Restricted Stock Units with a Market Condition (the Market Condition RSUs) The Compensation Committee of the Board of Directors of the Company approves and grants deferred stock awards of Market Condition RSUs (the Market Condition RSUs) to certain members of the Company’s management team under the Incentive Plan. The vesting of the Market Condition RSUs is based on a graded-vesting schedule ( one third three one 20 As of December 31, 2020, Stock-Based Payment Awards The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, no Stock option and restricted stock unit activity under the Company’s Incentive Plan for the years ended December 31, 2020 2019 Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2018 1,956,732 $ 4.25 1,233,762 $ 3.36 116,944 $ 4.19 Granted 943,424 3.28 1,652,720 2.31 605,005 1.98 Exercised (3,750 ) 2.98 - - - - Vested (RSUs) - - (813,762 ) 3.29 (3,778 ) 4.19 Cancelled/Forfeited (630,284 ) 3.96 (482,270 ) 3.42 (188,680 ) 4.18 Balance at December 31, 2019 2,266,122 3.93 1,590,450 2.27 529,491 1.67 Granted 894,154 2.61 1,027,486 2.75 332,622 2.98 Exercised (253,853 ) 3.94 - - - - Vested (RSUs) - - (930,985 ) 2.41 (240,205 ) 1.53 Cancelled/Forfeited (269,084 ) 3.68 (126,490 ) 3.13 (41,932 ) 3.04 Market Condition RSU - factor adjustment - - - - 233,055 1.47 Balance at December 31, 2020 2,637,339 $ 3.51 1,560,461 $ 2.44 813,031 $ 2.12 For Market Condition RSUs granted during the year ended December 31, 2019, 2020 December 31, 2020. Earnings per share Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: Year Ended December 31, 2020 2020 2019 Basic 38,640,284 37,813,580 Dilutive effect of equity awards - - Diluted 38,640,284 37,813,580 The Company has excluded from the shares used in calculating the diluted earnings per common share options, restricted stock units and Market Condition RSUs totaling 5,010,931 and 4,386,063, as of December 31, 2020 2019 The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and vesting of the restricted stock units. The following table summarizes outstanding and exercisable options as of December 31, 2020 ( Options Outstanding Options Exercisable Weighted Weighted Average Average Remaining Weighted Remaining Weighted Range of Contractual Average Aggregate Contractual Average Aggregate Exercise Number Life Exercise Intrinsic Shares Life Exercise Intrinsic Price Outstanding in Years Price Value Exercisable in Years Price Value $1.78 - 2.62 357,018 7.5 $ 2.27 $ 723 96,488 4.8 $ 2.29 $ 193 2.63 - 2.66 717,044 6.4 2.63 1,190 179,264 6.4 2.63 298 2.67 - 3.92 568,784 7.1 3.33 545 348,704 6.2 3.36 323 3.93 - 4.38 587,693 2.9 4.23 35 587,693 2.9 4.23 35 4.39 - 5.63 406,800 4.3 5.37 - 401,800 4.3 5.38 - $1.78 - 5.63 2,637,339 5.6 $ 3.51 $ 2,493 1,613,949 4.5 $ 4.04 $ 849 The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $4.29 as of December 31, 2020, December 31, 2020 not December 31, 2019. December 31, 2020 As of December 31, 2020, not Valuation and Expense Information under Stock-Based-Payment Accounting Stock-based compensation expense related to stock options, restricted stock units, Market Condition RSU’s and the ESPP for the years ended December 31, 2020 2019 Year Ended December 31, (in thousands) 2020 2019 Cost of revenues $ 65 $ 43 Sales and marketing expenses 263 119 General and administrative expenses 3,122 2,710 Research and development expenses 197 162 Total stock-based compensation expenses $ 3,647 $ 3,034 The Company did not The weighted-average estimated fair value per share of stock options granted during the year ended December 31, 2020 2019 2020 2019 Volatility 58.3 % 48.1 % Risk-free interest rate 0.3 % 2.1 % Expected holding period (in years) 4.4 4.7 Dividend Yield - % - % The weighted average estimated fair value per share of the Market Condition RSUs granted during the year ended December 31, 2020 2019 2020 2019 Volatility 80.6 % 59 % Risk-free interest rate 0.2 % 2 % Correlation coefficient 31.5 % 23.6 % Dividend Yield - % - % The Company used historical volatility to calculate the expected volatility. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options. The expected holding period of stock options represents the period of time options are expected to be outstanding and were based on historical experience. The vesting period ranges from one four ten

Note 11 - Long Term Debt

Note 11 - Long Term Debt	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	11. Long Term Debt As of December 31, 2020 December 31, 2019, December 31, (in thousands) 2020 2019 Term loan $ 40,000 $ 54,997 Revolving line 9,400 - Less: unamortized deferred financing costs (1,393 ) (1,180 ) Total debt 48,007 53,817 Less: current installments (2,000 ) (3,200 ) Less: excess cash flow sweep - (4,093 ) Current unamortized deferred financing costs 279 393 Long-term debt $ 46,286 $ 46,917 The aggregate amounts of debt maturing during the next five (in thousands) 2021 $ 2,000 2022 3,000 2023 3,000 2024 4,000 2025 37,400 $ 49,400 On December 22, 2020, none December 22, 2025. December 31, 2020, The Credit Agreement replaces the Company’s prior credit facility (the “Prior Credit Facility”) for which Cerberus Business Finance, LLC, served as collateral agent and administrative agent. The Prior Credit Facility consisted of a revolving credit facility and a term loan and was scheduled to expire on January 31, 2023. December 22, 2020, Borrowings under the Citizens Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on LIBOR for an interest period of one, two, three six no Commencing on March 31, 2021, three eight ninety December 31, 2021 may The Credit Agreement requires the Company pay (i) a fee on the average daily unused amount of the revolving loan of the Citizens Credit Facility payable at a rate which varies from 0.25% to 0.50% depending on the Company’s consolidated net leverage ratio, as determined in accordance with the Pricing Grid, (ii) a fee for each outstanding letter of credit at a rate per annum equal to the applicable interest rate margin for LIBOR Loans, as determined in accordance with the Pricing Grid, multiplied by the average daily amount available to be drawn under such letter of credit, and (iii) to the letter-of-credit issuer, a fronting fee which shall be at a rate agreed upon by the Company and the Lenders based on the average daily amount of the outstanding aggregate letter-of-credit obligations under the Credit Agreement. The Credit Agreement includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio, each of which will be tested at the end of each fiscal quarter of the Company. The Credit Agreement also includes customary events of default. As of December 31, 2020, On April 18, 2020, April 23, 2020, May 4, 2020. Derivatives The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not not By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged. On January 31, 2018, January 1, 2023 815 In connection with the Credit Agreement entered into on December 22, 2020, The following table presents the notional amount and fair value of the Company’s derivative instruments as of December 31, 2019. 31-Dec-19 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long-term liabilities $ 28,821 $ (603 ) (a) See Note 12 All of the Company’s derivative instruments are designated as hedging instruments. The Company has structured its interest rate swap agreements to be 100% no 815, The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the years ended December 31, 2020 2019: Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative (effective portion) Year Ended December 31, (in thousands) 2020 2019 Interest rate swaps $ (206 ) $ (572 ) The following table summarizes the reclassifications out of accumulated other comprehensive loss for the year ended December 31, 2020 2019: Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Year Ended December 31, Location of amount reclassified (in thousands) 2020 2019 into income (effective portion) Interest rate swaps $ 319 $ 139 Interest expense Interest rate swaps settlement 490 - Debt extinguishment and related costs Total $ 809 $ 139

Note 12 - Fair Value Measuremen

Note 12 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	12. Fair Value Measurements The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis: Fair Value as of December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities) Interest rate swap agreements $ - $ (603 ) $ - $ (603 ) The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date. The Company had no interest rate swap agreements outstanding as of December 31, 2020, December 22, 2020, 11.

Note 13 - Revenues

Note 13 - Revenues	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	13. Revenues The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2020 2019: Year Ended December 31, (in thousands) 2020 2019 Instruments, equipment, software and accessories $ 97,473 $ 110,220 Service, maintenance and warranty contracts 4,627 5,956 Total revenues $ 102,100 $ 116,176 Deferred revenue Changes in deferred revenue from service contracts and advance payments from customers for the years ended December 31, 2020 2019 Year Ended December 31, 2020 Service Customer (in thousands) Contracts Advances Total Balance, beginning of period $ 1,587 $ 2,362 $ 3,949 Deferral of revenue 3,329 1,302 4,631 Recognition of deferred revenue (3,298 ) (1,522 ) (4,820 ) Effect of foreign currency translation 11 - 11 Balance, end of period $ 1,629 $ 2,142 $ 3,771 Year Ended December 31, 2019 Service Customer (in thousands) Contracts Advances Total Balance, beginning of period $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 2,152 1,095 3,247 Recognition of deferred revenue (2,233 ) (894 ) (3,127 ) Effect of foreign currency translation 9 - 9 Balance, end of period $ 1,587 $ 2,362 $ 3,949 Allowance for Doubtful Accounts Allowance for doubtful accounts is based on the Company’s assessment of the collectability of customer accounts. A rollforward of allowance for doubtful accounts is as follows: Year Ended December 31, (in thousands) 2020 2019 Balance, beginning of period $ 325 $ 332 Bad debt expense 17 288 Charge-offs and other recoveries (124 ) (293 ) Effect of foreign currency translation 9 (2 ) Balance, end of period $ 227 $ 325 Concentrations No 10% December 31, 2020, 2019. December 31, 2020 2019, no 10% Warranties Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows: Beginning (Charges)\ Ending (in thousands) Balance Additions Credits Balance Year ended December 31, 2019 $ 391 10 (149 ) $ 252 Year ended December 31, 2020 $ 252 77 (143 ) $ 186

Note 14 - Income Tax

Note 14 - Income Tax	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14. Income Tax Income tax expense (benefit) for years ended December 31, 2020 2019 Year Ended December 31, (in thousands) 2020 2019 Current income tax (benefit) expense: Federal and state $ 169 $ (707 ) Foreign 492 290 661 (417 ) Deferred income tax (benefit) expense: Federal and state 245 (281 ) Foreign (388 ) (117 ) (143 ) (398 ) Total income tax (benefit) expense $ 518 $ (815 ) The effective tax rate for the year ended December 31, 2020 14.9% 2019. Income tax benefit for the years ended December 31, 2020 2019 21% Year Ended December 31, (in thousands) 2020 2019 Computed "expected" income tax benefit $ (1,531 ) 21.0 % $ (1,161 ) 21.0 % Increase (decrease) in income taxes resulting from: Permanent differences, net 141 (1.9 )% 241 (4.4 )% Foreign tax rate differential (14 ) 0.2 % 42 (0.8 )% State income taxes, net of federal income tax benefit (77 ) 1.1 % (74 ) 1.3 % Non-deductible stock compensation expense 94 (1.3 )% 205 (3.7 )% Tax credits (192 ) 2.6 % 220 (4.0 )% Change in reserve for uncertain tax position 259 (3.6 )% (111 ) 2.0 % Impact of change to prior year tax accruals 168 (2.3 )% 314 (5.7 )% Change in valuation allowance allocated to income tax 2,130 (29.2 )% (578 ) 10.5 % Other (460 ) 6.3 % 87 (1.4 )% Total income tax expense (benefit) $ 518 (7.1 )% $ (815 ) 14.8 % The Company’s policy is to account for Global Intangible Low-Taxed income (GILTI) as a period cost. Income tax (benefit) expense is based on the following pre-tax (loss) income from operations: Year Ended December 31, (in thousands) 2020 2019 Domestic $ (7,954 ) $ (5,616 ) Foreign 662 114 Total $ (7,292 ) $ (5,502 ) The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities at December 31, 2020 2019 Year Ended December 31, (in thousands) 2020 2019 Deferred income tax assets: Inventory $ 1,144 $ 1,079 Operating loss and credit carryforwards 19,220 18,802 Accrued expenses 555 654 Deferred interest expense 1,476 1,475 Stock compensation 1,079 1,011 Lease liability 1,823 2,081 Other assets 458 223 Total gross deferred assets 25,755 25,325 Less: valuation allowance (16,682 ) (13,745 ) Deferred tax assets: $ 9,073 $ 11,580 Deferred income tax liabilities: Indefinite-lived intangible assets $ 1,822 $ 2,048 Definite-lived intangible assets 7,493 9,168 Right-of-use asset 1,388 1,580 Other Liabilities 14 507 Total deferred tax liabilities 10,717 13,303 Deferred income tax liability, net $ (1,644 ) $ (1,723 ) Deferred income tax assets and liabilities by classification on the consolidated balance sheets were as follows: Year Ended December 31, (in thousands) 2020 2019 Deferred tax assets (included in other long-term assets) $ 255 $ 251 Deferred income tax liabilities (1,899 ) (1,974 ) Deferred income tax liability, net $ (1,644 ) $ (1,723 ) As of December 31, 2020 2019, December 31, 2020 December 31, 2019 2020 December 31, 2020 2019 At December 31, 2020, 2021 2037, 2021 2040. 2021, 2021. not 2017 2021. may one 382 383. As of December 31, 2020 December 31, 2019, December 31, 2020, At December 31, 2020 2019 (in thousands) Balance at December 31, 2018 $ 1,860 Additions based on tax positions of prior years 68 Decreases based on tax positions of prior years (133 ) Additions based on tax positions of current years 21 Settlements (398 ) Decreases based on tax positions of acquired entities (65 ) Balance at December 31, 2019 1,353 Additions based on tax positions of prior years 157 Decreases based on tax positions of prior years (11 ) Additions based on tax positions of current years 213 Settlements (39 ) Balance at December 31, 2020 $ 1,673 In 2019, 2020, two The Company anticipates that the total unrecognized tax benefits will be reduced within the next 12 not December 31, 2020 2019, The Company or one no 2016. 2001 no On March 27, 2020, 163j 50% 30% 2019 2020. December 31, 2017, 2018, no December 31, 2020. 50% December 31, 2021, 50% December 31, 2022.

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	15. Commitments and Contingent Liabilities On April 14, 2017, 2013, third third 2012 2013. The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not not not one

Note 16 - Segment and Related I

Note 16 - Segment and Related Information	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segment and Related Information Operating segments are determined by products and services provided by each segment, internal organization structure, the manner in which operations are managed, criteria used by the Chief Operating Decision Maker, or CODM, to assess the segment performance, as well as resource allocation and the availability of discrete financial information. The Company has one The following tables summarize additional selected financial information of the Company’s operations by geographic location. Revenue by geographic destination consist of the following: Year Ended December 31, (in thousands) 2020 2019 United States $ 42,054 $ 47,792 Europe 29,938 35,128 Asia 23,884 25,041 Rest of the world 6,224 8,215 Total revenues $ 102,100 $ 116,176 Long-lived assets by geographic area consist of the following: December 31, (in thousands) 2020 2019 United States $ 36,568 $ 41,993 Germany 4,958 5,468 Rest of the world 3,092 3,048 Total long-lived assets (a) $ 44,618 $ 50,509 (a) consists of operating lease right-of-use assets, property, plant and equipment, net and amortizable intangible assets, net. Net assets by geographic area consist of the following: December 31, (in thousands) 2020 2019 United States $ 32,457 $ 37,726 Germany 18,697 17,340 United Kingdom 8,867 11,254 Rest of the world 16,660 15,374 Total net assets $ 76,681 $ 81,694

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	(a) Principles of Consolidation The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	(b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for inventory excess and obsolescence, income tax and reserves for bad debts. In addition, certain estimates are required in order to determine the value of assets and liabilities associated with acquisitions, as well as the Company’s defined benefit pension obligations. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	(c) Cash and Cash Equivalents The Company considers all highly liquid instruments with original maturities of three may not not
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	(d) Allowance for Doubtful Accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on considering factors such as historical experience, credit quality, known troubled accounts, historical experience, factors that may
Inventory, Policy [Policy Text Block]	(e) Inventories The Company values its inventories at the lower of the actual cost to purchase ( first first
Property, Plant and Equipment, Policy [Policy Text Block]	(f) Property, Plant and Equipment Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows: Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10 Property and equipment held under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.
Lessee, Leases [Policy Text Block]	(g) Leases The Company accounts for its leases in accordance with ASC 842 12 not The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (ROU) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not
Income Tax, Policy [Policy Text Block]	(h) Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company recognizes the effect of income tax positions only if those positions are more likely than not 50%
Foreign Currency Transactions and Translations Policy [Policy Text Block]	(i) Foreign Currency Translation The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of its foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive (loss) income (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in net (loss) income.
Earnings Per Share, Policy [Policy Text Block]	(j) Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.
Comprehensive Income (Loss) [Policy Text Block]	(k) Comprehensive (Loss) Income In accordance with ASC 220,
Revenue from Contract with Customer [Policy Text Block]	(l) Revenue Recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, including the United States National Institutes of Health (NIH) and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer (OEM) customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may not Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may may, no may may not 606. Service revenues consist of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not one one For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to any and all remaining performance obligations are generally expected to be recognized in one one Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not not The Company’s payment terms are generally from zero sixty Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not Disaggregation of revenue Refer to Note 13 16
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	(m) Valuation of Identifiable Intangible Assets Acquired in Business Combinations The determination of the fair value of intangible assets, which represents a significant portion of the purchase price in the Company’s acquisitions, requires the use of significant judgment with regard to (i) the fair value; and (ii) whether such intangibles are amortizable or not
Goodwill and Intangible Assets, Policy [Policy Text Block]	(n) Goodwill and Other Intangible Assets Goodwill and unamortizable intangible assets acquired in a business combination and determined to have an indefinite useful life are not 350, For the purpose of its goodwill analysis, the Company has one fourth not December 31, 2020, none The Company evaluates indefinite-lived intangible assets for impairment annually and when events occur, or circumstances change that may 4
Impairment of Long Lived Assets [Policy Text Block ]	(o) Impairment of Long-Lived Assets The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets in accordance with ASC 360, may not December 31, 2020, none
Derivatives, Policy [Policy Text Block]	(p) Derivatives The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not not The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. The Company discontinues hedge accounting prospectively when it determines that the derivative is no not In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not
Fair Value of Financial Instruments, Policy [Policy Text Block]	(q) Fair Value of Financial Instruments The carrying values of the Company’s cash and cash equivalents, trade accounts receivable and trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity. Financial reporting standards define a fair value hierarchy that consists of three § Level 1 § Level 2 not § Level 3
Share-based Payment Arrangement [Policy Text Block]	(r) Stock-based Compensation The Company accounts for stock-based payment awards in accordance with the provisions of ASC 718, 2000 Stock-based compensation expense recognized is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company values stock-based payment awards, except restricted stock units at grant date using the Black-Scholes option-pricing model. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using an option-pricing model or Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables. These variables include, but are not The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant and are recorded as compensation expense on a straight-line basis over the applicable service period, which ranges from one four Stock-based compensation expense recognized under ASC 718 December 31, 2020 2019 10
New Accounting Pronouncements, Policy [Policy Text Block]	(s) Recent Accounting Pronouncements Accounting Pronouncements to be Adopted In September 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 Instruments (ASU 2016 13 may 2016 13 2016 13 December 15, 2022, 2016 13 In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 2019 12 2019 12 January 1, 2021. not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment, Useful Lives [Table Text Block]	Machinery and equipment (years) 3 - 10 Computer equipment and software (years) 3 - 7 Furniture and fixtures (years) 5 - 10

Note 3 - Accumulated Other Co_2

Note 3 - Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign currency Derivatives translation qualifying as Defined benefit (in thousands) adjustments hedges pension plans Total Balance at December 31, 2018 $ (12,630 ) $ (170 ) $ (732 ) $ (13,532 ) Other comprehensive income (loss) before reclassifications (543 ) (572 ) 1,258 143 Amounts reclassified from AOCI - 139 561 700 Net other comprehensive (loss) income (543 ) (433 ) 1,819 843 Balance at December 31, 2019 $ (13,173 ) $ (603 ) $ 1,087 $ (12,689 ) Other comprehensive income (loss) before reclassifications 1,700 (206 ) (2,785 ) (1,291 ) Amounts reclassified from AOCI - 809 105 914 Net other comprehensive (loss) income 1,700 603 (2,680 ) (377 ) Balance at December 31, 2020 $ (11,473 ) $ - $ (1,593 ) $ (13,066 )
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Affected line item in the Year Ended December 31, (in thousands) Statements of Operations 2020 2019 Amounts Reclassified From AOCI Derivatives qualifying as hedges Realized loss on derivatives qualifying as hedges Interest expense, net $ 319 $ 139 Realized loss on derivatives qualifying as hedges Debt extinguishment and related costs 490 - Income tax Income tax (benefit) expense - - 809 139 Defined benefit pension plans Amortization of net losses included in net periodic pension costs General and administrative expenses 105 561 Income tax Income tax (benefit) expense - - 105 561 Total reclassifications $ 914 $ 700

Note 4 - Goodwill and Intangi_2

Note 4 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Goodwill [Table Text Block]	December 31, (in thousands) 2020 2019 Balance at beginning of year $ 57,381 $ 57,304 Effect of change in currency translation 1,209 77 Balance at end of year $ 58,590 $ 57,381
Schedule of Intangible Assets and Goodwill [Table Text Block]	December 31, 2020 2019 Weighted (in thousands) Amortizable intangible assets: Average Life* (Years) Gross Accumulated Amortization Net Gross Accumulated Amortization Net Distribution agreements/customer relationships 8.8 $ 18,237 $ (7,746 ) $ 10,491 $ 17,891 $ (6,340 ) $ 11,551 Existing technology 5.2 38,761 (20,674 ) 18,087 41,222 (19,698 ) 21,524 Trade names and patents 5.4 8,681 (4,362 ) 4,319 7,910 (3,715 ) 4,195 Total amortizable intangible assets $ 65,679 $ (32,782 ) $ 32,897 $ 67,023 $ (29,753 ) $ 37,270 Indefinite-lived intangible assets: 254 1,135 Total intangible assets $ 33,151 $ 38,405
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization Year Ending December 31, Expense (in thousands) 2021 $ 5,774 2022 5,740 2023 5,627 2024 5,318 2025 4,204 Thereafter 6,234 Total $ 32,897

Note 5 - Balance Sheet Inform_2

Note 5 - Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, (in thousands) 2020 2019 Finished goods $ 4,938 $ 5,561 Work in process 3,513 3,153 Raw materials 13,811 13,347 Total $ 22,262 $ 22,061
Other Current Liabilities [Table Text Block]	December 31, (in thousands) 2020 2019 Compensation $ 3,715 2,554 Professional fees 432 395 Warranty costs 185 252 Customer related costs 1,093 963 Interest 46 425 Accrued income taxes 286 609 Other 1,721 1,502 Total $ 7,478 $ 6,700
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 2020 2019 Machinery and equipment $ 7,450 $ 7,198 Computer equipment and software 9,114 8,954 Leasehold improvements 2,540 2,151 Furniture and fixtures 1,353 1,321 Automobiles 100 92 20,557 19,716 Less: accumulated depreciation (16,597 ) (14,940 ) Property, plant and equipment, net $ 3,960 $ 4,776

Note 6 - Restructuring and Ot_2

Note 6 - Restructuring and Other Exit Costs (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Restructuring and Related Costs [Table Text Block]	Cost of Severance (in thousands) Revenue Costs Impairment Other Total Restructuring and other exit costs $ 235 $ 530 $ 460 $ 129 $ 1,354 Non-cash charges (235 ) - (460 ) (10 ) (705 ) Cash payments - (166 ) - (115 ) (281 ) Balance at December 31, 2019 - 364 - 4 368 Restructuring and other exit costs - 1,625 - 408 2,033 Non-cash charges - - - (168 ) (168 ) Cash payments - (1,719 ) - (226 ) (1,945 ) Balance at December 31, 2020 $ - $ 270 $ - $ 18 $ 288

Note 8 - Employee Benefit Pla_2

Note 8 - Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Costs of Retirement Plans [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Interest cost $ 391 $ 484 Expected return on plan assets (733 ) (761 ) Net amortization loss 105 336 Recognition of net loss due to settlements 22 228 Net periodic benefit (credit) cost $ (215 ) $ 287
Schedule of Changes in Projected Benefit Obligations [Table Text Block]	December 31, (in thousands) 2020 2019 Change in benefit obligation: Balance at beginning of year $ 20,027 $ 18,701 Interest cost 391 484 Actuarial loss 4,814 1,513 Settlements due to transfers paid (205 ) (871 ) Benefits paid (476 ) (447 ) Currency translation adjustment 968 647 Balance at end of year $ 25,519 $ 20,027
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]	December 31, (in thousands) 2020 2019 Change in fair value of plan assets: Balance at beginning of year $ 21,114 $ 17,819 Actual return on plan assets 1,690 3,172 Employer contributions 901 831 Settlement due to transfers paid (159 ) (931 ) Benefits paid (476 ) (447 ) Currency translation adjustment 856 670 Balance at end of year $ 23,926 $ 21,114
Schedule of Net Funded Status [Table Text Block]	December 31, (in thousands) 2020 2019 Benefit obligation $ (25,519 ) $ (20,027 ) Fair value of plan asset 23,926 21,114 Net funded status $ (1,593 ) $ 1,087
Schedule of Amounts Recognized in Balance Sheet [Table Text Block]	December 31, (in thousands) 2020 2019 Other long term (liabilities) assets $ (1,593 ) $ 1,087 Deferred income taxes - - Accumulated other comprehensive loss $ (1,593 ) $ 1,087
Defined Benefit Plan, Assumptions [Table Text Block]	Year Ended December 31, 2020 2019 Discount rate 1.4 % 2.02 % Expected return on assets 3.45 % 3.84 %
Schedule of Allocation of Plan Assets [Table Text Block]	December 31, (in thousands) 2020 2019 Asset category: Equity securities $ 12,047 50 % $ 11,534 55 % Debt securities 4,605 19 % 3,919 19 % Liability driven investment funds 5,168 22 % 3,615 17 % Cash and cash equivalents 1,860 8 % 1,514 7 % Other 246 1 % 532 3 % Total $ 23,926 100 % $ 21,114 100 %
Defined Benefit Plan, Plan Assets, Category [Table Text Block]	December 31, (in thousands) 2020 2019 Quoted Prices in Active Markets for Identical Assets (Level 1) $ 1,860 $ 1,514 Significant Other Observable Inputs (Level 2) 22,066 19,600 Significant Other Unobservable Inputs (Level 3) - - Total $ 23,926 $ 21,114

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Operating lease cost $ 2,153 $ 2,084 Short term lease cost 175 245 Sublease income (183 ) (429 ) Total lease cost $ 2,145 $ 1,900
Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: $ 2,717 $ 2,530 Right-of-use assets obtained in exchange for lease obligations: $ 455 $ 177
Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]	December 31, (in thousands) 2020 2019 Operating lease right-of use assets $ 7,761 $ 8,463 Current portion, operating lease liabilities $ 2,111 $ 2,424 Operating lease liabilities, long term 7,481 8,224 Total operating lease liabilities $ 9,592 $ 10,648 Weighted average remaining lease term (in years) 7.4 8.1 Weighted average discount rate 9.3 % 9.2 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(in thousands) Operating Leases 2021 $ 2,111 2022 2,018 2023 1,970 2024 1,715 2025 1,000 Thereafter 4,854 Total lease payments 13,668 Less interest (4,076 ) Total operating lease liabilities $ 9,592

Note 10 - Capital Stock and S_2

Note 10 - Capital Stock and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]	Stock Options Restricted Stock Units Market Condition RSU's Weighted Stock Average Restricted Market Options Exercise Stock Units Grant Date Condition RSU's Grant Date Outstanding Price Outstanding Fair Value Outstanding Fair Value Balance at December 31, 2018 1,956,732 $ 4.25 1,233,762 $ 3.36 116,944 $ 4.19 Granted 943,424 3.28 1,652,720 2.31 605,005 1.98 Exercised (3,750 ) 2.98 - - - - Vested (RSUs) - - (813,762 ) 3.29 (3,778 ) 4.19 Cancelled/Forfeited (630,284 ) 3.96 (482,270 ) 3.42 (188,680 ) 4.18 Balance at December 31, 2019 2,266,122 3.93 1,590,450 2.27 529,491 1.67 Granted 894,154 2.61 1,027,486 2.75 332,622 2.98 Exercised (253,853 ) 3.94 - - - - Vested (RSUs) - - (930,985 ) 2.41 (240,205 ) 1.53 Cancelled/Forfeited (269,084 ) 3.68 (126,490 ) 3.13 (41,932 ) 3.04 Market Condition RSU - factor adjustment - - - - 233,055 1.47 Balance at December 31, 2020 2,637,339 $ 3.51 1,560,461 $ 2.44 813,031 $ 2.12
Schedule of Weighted Average Number of Shares [Table Text Block]	Year Ended December 31, 2020 2020 2019 Basic 38,640,284 37,813,580 Dilutive effect of equity awards - - Diluted 38,640,284 37,813,580
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Weighted Average Average Remaining Weighted Remaining Weighted Range of Contractual Average Aggregate Contractual Average Aggregate Exercise Number Life Exercise Intrinsic Shares Life Exercise Intrinsic Price Outstanding in Years Price Value Exercisable in Years Price Value $1.78 - 2.62 357,018 7.5 $ 2.27 $ 723 96,488 4.8 $ 2.29 $ 193 2.63 - 2.66 717,044 6.4 2.63 1,190 179,264 6.4 2.63 298 2.67 - 3.92 568,784 7.1 3.33 545 348,704 6.2 3.36 323 3.93 - 4.38 587,693 2.9 4.23 35 587,693 2.9 4.23 35 4.39 - 5.63 406,800 4.3 5.37 - 401,800 4.3 5.38 - $1.78 - 5.63 2,637,339 5.6 $ 3.51 $ 2,493 1,613,949 4.5 $ 4.04 $ 849
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Cost of revenues $ 65 $ 43 Sales and marketing expenses 263 119 General and administrative expenses 3,122 2,710 Research and development expenses 197 162 Total stock-based compensation expenses $ 3,647 $ 3,034
Monte-Carlo Valuation Simulation [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Volatility 80.6 % 59 % Risk-free interest rate 0.2 % 2 % Correlation coefficient 31.5 % 23.6 % Dividend Yield - % - %
Black Scholes Option Pricing Model [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Volatility 58.3 % 48.1 % Risk-free interest rate 0.3 % 2.1 % Expected holding period (in years) 4.4 4.7 Dividend Yield - % - %

Note 11 - Long Term Debt (Table

Note 11 - Long Term Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Debt [Table Text Block]	December 31, (in thousands) 2020 2019 Term loan $ 40,000 $ 54,997 Revolving line 9,400 - Less: unamortized deferred financing costs (1,393 ) (1,180 ) Total debt 48,007 53,817 Less: current installments (2,000 ) (3,200 ) Less: excess cash flow sweep - (4,093 ) Current unamortized deferred financing costs 279 393 Long-term debt $ 46,286 $ 46,917
Schedule of Maturities of Long-term Debt [Table Text Block]	(in thousands) 2021 $ 2,000 2022 3,000 2023 3,000 2024 4,000 2025 37,400 $ 49,400
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	31-Dec-19 Notional Amount Fair Value (a) Derivatives instruments Balance sheet classification (in thousands) Interest rate swaps Other long-term liabilities $ 28,821 $ (603 )
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Derivatives in Hedging Relationships Amount of gain (loss) recognized in OCI on derivative (effective portion) Year Ended December 31, (in thousands) 2020 2019 Interest rate swaps $ (206 ) $ (572 ) Details about AOCI Components Amount reclassified from AOCI into income (effective portion) Year Ended December 31, Location of amount reclassified (in thousands) 2020 2019 into income (effective portion) Interest rate swaps $ 319 $ 139 Interest expense Interest rate swaps settlement 490 - Debt extinguishment and related costs Total $ 809 $ 139

Note 12 - Fair Value Measurem_2

Note 12 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value as of December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Total Assets (Liabilities) Interest rate swap agreements $ - $ (603 ) $ - $ (603 )

Note 13 - Revenues (Tables)

Note 13 - Revenues (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Instruments, equipment, software and accessories $ 97,473 $ 110,220 Service, maintenance and warranty contracts 4,627 5,956 Total revenues $ 102,100 $ 116,176 Year Ended December 31, 2020 Service Customer (in thousands) Contracts Advances Total Balance, beginning of period $ 1,587 $ 2,362 $ 3,949 Deferral of revenue 3,329 1,302 4,631 Recognition of deferred revenue (3,298 ) (1,522 ) (4,820 ) Effect of foreign currency translation 11 - 11 Balance, end of period $ 1,629 $ 2,142 $ 3,771 Year Ended December 31, 2019 Service Customer (in thousands) Contracts Advances Total Balance, beginning of period $ 1,659 $ 2,161 $ 3,820 Deferral of revenue 2,152 1,095 3,247 Recognition of deferred revenue (2,233 ) (894 ) (3,127 ) Effect of foreign currency translation 9 - 9 Balance, end of period $ 1,587 $ 2,362 $ 3,949
Financing Receivable, Allowance for Credit Loss [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Balance, beginning of period $ 325 $ 332 Bad debt expense 17 288 Charge-offs and other recoveries (124 ) (293 ) Effect of foreign currency translation 9 (2 ) Balance, end of period $ 227 $ 325
Schedule of Product Warranty Liability [Table Text Block]	Beginning (Charges)\ Ending (in thousands) Balance Additions Credits Balance Year ended December 31, 2019 $ 391 10 (149 ) $ 252 Year ended December 31, 2020 $ 252 77 (143 ) $ 186

Note 14 - Income Tax (Tables)

Note 14 - Income Tax (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Current income tax (benefit) expense: Federal and state $ 169 $ (707 ) Foreign 492 290 661 (417 ) Deferred income tax (benefit) expense: Federal and state 245 (281 ) Foreign (388 ) (117 ) (143 ) (398 ) Total income tax (benefit) expense $ 518 $ (815 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Computed "expected" income tax benefit $ (1,531 ) 21.0 % $ (1,161 ) 21.0 % Increase (decrease) in income taxes resulting from: Permanent differences, net 141 (1.9 )% 241 (4.4 )% Foreign tax rate differential (14 ) 0.2 % 42 (0.8 )% State income taxes, net of federal income tax benefit (77 ) 1.1 % (74 ) 1.3 % Non-deductible stock compensation expense 94 (1.3 )% 205 (3.7 )% Tax credits (192 ) 2.6 % 220 (4.0 )% Change in reserve for uncertain tax position 259 (3.6 )% (111 ) 2.0 % Impact of change to prior year tax accruals 168 (2.3 )% 314 (5.7 )% Change in valuation allowance allocated to income tax 2,130 (29.2 )% (578 ) 10.5 % Other (460 ) 6.3 % 87 (1.4 )% Total income tax expense (benefit) $ 518 (7.1 )% $ (815 ) 14.8 %
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Domestic $ (7,954 ) $ (5,616 ) Foreign 662 114 Total $ (7,292 ) $ (5,502 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 Deferred income tax assets: Inventory $ 1,144 $ 1,079 Operating loss and credit carryforwards 19,220 18,802 Accrued expenses 555 654 Deferred interest expense 1,476 1,475 Stock compensation 1,079 1,011 Lease liability 1,823 2,081 Other assets 458 223 Total gross deferred assets 25,755 25,325 Less: valuation allowance (16,682 ) (13,745 ) Deferred tax assets: $ 9,073 $ 11,580 Deferred income tax liabilities: Indefinite-lived intangible assets $ 1,822 $ 2,048 Definite-lived intangible assets 7,493 9,168 Right-of-use asset 1,388 1,580 Other Liabilities 14 507 Total deferred tax liabilities 10,717 13,303 Deferred income tax liability, net $ (1,644 ) $ (1,723 ) Year Ended December 31, (in thousands) 2020 2019 Deferred tax assets (included in other long-term assets) $ 255 $ 251 Deferred income tax liabilities (1,899 ) (1,974 ) Deferred income tax liability, net $ (1,644 ) $ (1,723 )
Summary of Income Tax Contingencies [Table Text Block]	(in thousands) Balance at December 31, 2018 $ 1,860 Additions based on tax positions of prior years 68 Decreases based on tax positions of prior years (133 ) Additions based on tax positions of current years 21 Settlements (398 ) Decreases based on tax positions of acquired entities (65 ) Balance at December 31, 2019 1,353 Additions based on tax positions of prior years 157 Decreases based on tax positions of prior years (11 ) Additions based on tax positions of current years 213 Settlements (39 ) Balance at December 31, 2020 $ 1,673

Note 16 - Segment and Related_2

Note 16 - Segment and Related Information (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, (in thousands) 2020 2019 United States $ 42,054 $ 47,792 Europe 29,938 35,128 Asia 23,884 25,041 Rest of the world 6,224 8,215 Total revenues $ 102,100 $ 116,176
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	December 31, (in thousands) 2020 2019 United States $ 36,568 $ 41,993 Germany 4,958 5,468 Rest of the world 3,092 3,048 Total long-lived assets (a) $ 44,618 $ 50,509
Schedule of Net Assets By Geographic Areas [Table Text Block]	December 31, (in thousands) 2020 2019 United States $ 32,457 $ 37,726 Germany 18,697 17,340 United Kingdom 8,867 11,254 Rest of the world 16,660 15,374 Total net assets $ 76,681 $ 81,694

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Goodwill, Impairment Loss	$ 0
Impairment of Long-Lived Assets Held-for-use	$ 0
Minimum [Member]
Customer Payments Term (Day)	0 days
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	1 year
Maximum [Member]
Customer Payments Term (Day)	60 days
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	4 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2020
Machinery and Equipment [Member] | Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, plant and equipment useful life (Year)	10 years
Computer Equipment and Software [member] | Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Computer Equipment and Software [member] | Maximum [Member]
Property, plant and equipment useful life (Year)	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, plant and equipment useful life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, plant and equipment useful life (Year)	10 years

Note 3 - Accumulated Other Co_3

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 81,694	$ 82,724
Other comprehensive (loss) income	(377)	843
Balance	76,681	81,694
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(13,173)	(12,630)
Other comprehensive income (loss) before reclassifications	1,700	(543)
Amounts reclassified from AOCI	0	0
Other comprehensive (loss) income	1,700	(543)
Balance	(11,473)	(13,173)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Balance	(603)	(170)
Other comprehensive income (loss) before reclassifications	(206)	(572)
Amounts reclassified from AOCI	809	139
Other comprehensive (loss) income	603	(433)
Balance	0	(603)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	1,087	(732)
Other comprehensive income (loss) before reclassifications	(2,785)	1,258
Amounts reclassified from AOCI	105	561
Other comprehensive (loss) income	(2,680)	1,819
Balance	(1,593)	1,087
AOCI Attributable to Parent [Member]
Balance	(12,689)	(13,532)
Other comprehensive income (loss) before reclassifications	(1,291)	143
Amounts reclassified from AOCI	914	700
Other comprehensive (loss) income	(377)	843
Balance	$ (13,066)	$ (12,689)

Note 3 - Accumulated Other Co_4

Note 3 - Accumulated Other Comprehensive Loss - Reclassified out of AOCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Realized loss on derivatives qualifying as hedges	$ 4,831	$ 5,410
Realized loss on derivatives qualifying as hedges	1,876	0
Income tax	518	(815)
Total reclassifications	7,810	4,687
General and administrative expenses	23,509	22,760
Reclassification out of Accumulated Other Comprehensive Income [Member]
Total reclassifications	914	700
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Realized loss on derivatives qualifying as hedges	319	139
Realized loss on derivatives qualifying as hedges	490	0
Income tax	0	0
Total reclassifications	809	139
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Income tax	0	0
Total reclassifications	105	561
General and administrative expenses	$ 105	$ 561

Note 4 - Goodwill and Intangi_3

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fully Amortized Intangible Assets, Retired	$ 3,500
Finite-Lived Intangible Assets, Gross, Total	65,679	$ 67,023
Impairment of Intangible Assets (Excluding Goodwill), Total	0
Asset Impairment Charges, Total	0	1,460
Restructuring Charges, Total	2,033	1,354
Other Asset Impairment Charges		100
Amortization of Intangible Assets, Total	5,710	5,746
Facility Closing [Member]
Restructuring Charges, Total		500
Indefinite-Lived Trade Names Reclassified to Finite-Lived [Member]
Finite-Lived Intangible Assets, Gross, Total	$ 900
In Process Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 900

Note 4 - Goodwill and Intangi_4

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance at beginning of year	$ 57,381	$ 57,304
Effect of change in currency translation	1,209	77
Balance at end of year	$ 58,590	$ 57,381

Note 4 - Goodwill and Intangi_5

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Gross		$ 65,679	$ 67,023
Total amortizable intangible assets		(32,782)	(29,753)
Finite-Lived Intangible Assets, Net		32,897	37,270
Indefinite-lived intangible assets:		254	1,135
Total intangible assets, Net		$ 33,151	38,405
Distribution Agreements/Customer Relationships [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	8 years 9 months 18 days
Finite-Lived Intangible Assets, Gross		$ 18,237	17,891
Total amortizable intangible assets		(7,746)	(6,340)
Finite-Lived Intangible Assets, Net		$ 10,491	11,551
Existing Technology [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)	[1]	5 years 2 months 12 days
Finite-Lived Intangible Assets, Gross		$ 38,761	41,222
Total amortizable intangible assets		(20,674)	(19,698)
Finite-Lived Intangible Assets, Net		$ 18,087	21,524
Trade Names and Patents [Member]
Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)		5 years 4 months 24 days
Finite-Lived Intangible Assets, Gross		$ 8,681	7,910
Total amortizable intangible assets		(4,362)	(3,715)
Finite-Lived Intangible Assets, Net		$ 4,319	$ 4,195
[1]	Weighted average life as of December 31, 2020.

Note 4 - Goodwill and Intangi_6

Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
2021	$ 5,774
2022	5,740
2023	5,627
2024	5,318
2025	4,204
Thereafter	6,234
Total	$ 32,897	$ 37,270

Note 5 - Balance Sheet Inform_3

Note 5 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finished goods	$ 4,938	$ 5,561
Work in process	3,513	3,153
Raw materials	13,811	13,347
Total	$ 22,262	$ 22,061

Note 5 - Balance Sheet Inform_4

Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Compensation	$ 3,715	$ 2,554
Professional fees	432	395
Warranty costs	185	252
Customer related costs	1,093	963
Interest	46	425
Accrued income taxes	286	609
Other	1,721	1,502
Total	$ 7,478	$ 6,700

Note 5 - Balance Sheet Inform_5

Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Gross	$ 20,557	$ 19,716
Less: accumulated depreciation	(16,597)	(14,940)
Property, plant and equipment, net	3,960	4,776
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	7,450	7,198
Computer Equipment and Software [member]
Property, Plant and Equipment, Gross	9,114	8,954
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,540	2,151
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	1,353	1,321
Automobiles [Member]
Property, Plant and Equipment, Gross	$ 100	$ 92

Note 6 - Restructuring and Ot_3

Note 6 - Restructuring and Other Exit Costs (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restructuring Reserve, Ending Balance	$ 288	$ 368
Restructuring Charges, Total	2,033	1,354
Selling, General and Administrative Expenses [Member]
Restructuring Charges, Total	$ 2,000	700
Impairment Charges [Member]
Restructuring Charges, Total		500
Cost of Sales [Member]
Restructuring Charges, Total		200
Facility Closing [Member]
Restructuring Charges, Total		$ 500

Note 6 - Restructuring and Ot_4

Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restructuring and other exit costs	$ 2,033	$ 1,354
Non-cash charges	(168)	(705)
Cash payments	(1,945)	(281)
Balance	368
Balance	288	368
Cost of Revenues [Member]
Restructuring and other exit costs	0	235
Non-cash charges	0	(235)
Cash payments	0	0
Balance	0
Balance	0	0
Employee Severance [Member]
Restructuring and other exit costs	1,625	530
Non-cash charges	0	0
Cash payments	(1,719)	(166)
Balance	364
Balance	270	364
Impairment [Member]
Restructuring and other exit costs	0	460
Non-cash charges	0	(460)
Cash payments	0	0
Balance	0
Balance	0	0
Other Restructuring [Member]
Restructuring and other exit costs	408	129
Non-cash charges	(168)	(10)
Cash payments	(226)	(115)
Balance	4
Balance	$ 18	$ 4

Note 7 - Related Party Transa_2

Note 7 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
The Multi Channel Systems Facility and Triangle BioSystems Lease Agreements [Member]
Operating Lease, Expense	$ 0.3	$ 0.3

Note 8 - Employee Benefit Pla_3

Note 8 - Employee Benefit Plans (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan, Cost	$ 0.7	$ 0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year One	0.6
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	0.6
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	0.8
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	0.8
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years	4.7
Minimum [Member]
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	$ 1

Note 8 - Employee Benefit Pla_4

Note 8 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Interest cost	$ 391	$ 484
Expected return on plan assets	(733)	(761)
Net amortization loss	105	336
Recognition of net loss due to settlements	22	228
Net periodic benefit (credit) cost	$ (215)	$ 287

Note 8 - Employee Benefit Pla_5

Note 8 - Employee Benefit Plans - Change in Benefit Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Benefit Obligation, Balance	$ 20,027	$ 18,701
Interest cost	391	484
Actuarial loss	4,814	1,513
Settlements due to transfers paid	(205)	(871)
Benefits paid	(476)	(447)
Currency translation adjustment	968	647
Defined Benefit Plan, Benefit Obligation, Balance	$ 25,519	$ 20,027

Note 8 - Employee Benefit Pla_6

Note 8 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 21,114	$ 17,819
Actual return on plan assets	1,690	3,172
Employer contributions	901	831
Settlement due to transfers paid	(159)	(931)
Benefits paid	(476)	(447)
Currency translation adjustment	856	670
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 23,926	$ 21,114

Note 8 - Employee Benefit Pla_7

Note 8 - Employee Benefit Plans - Change in Benefit Obligation (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Benefit obligation	$ (25,519)	$ (20,027)	$ (18,701)
Fair value of plan asset	23,926	21,114	$ 17,819
Net funded status	$ (1,593)	$ 1,087

Note 8 - Employee Benefit Pla_8

Note 8 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Net funded status	$ (1,593)	$ 1,087
Other Noncurrent Liabilities [Member]
Net funded status	(1,593)	1,087
Deferred Income Tax Assets [Member]
Net funded status	$ 0	$ 0

Note 8 - Employee Benefit Pla_9

Note 8 - Employee Benefit Plans - Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Discount rate	1.40%	2.02%
Expected return on assets	3.45%	3.84%

Note 8 - Employee Benefit Pl_10

Note 8 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan, Fair Value of Plan Assets		$ 23,926	$ 21,114	$ 17,819
Defined Benefit Plan, Actual Plan Asset Allocations		100.00%	100.00%
Defined Benefit Plan, Equity Securities [Member]
Defined Benefit Plan, Fair Value of Plan Assets		$ 12,047	$ 11,534
Defined Benefit Plan, Actual Plan Asset Allocations		50.00%	55.00%
Debt Security, Corporate, US [Member]
Defined Benefit Plan, Fair Value of Plan Assets	[1]	$ 4,605	$ 3,919
Defined Benefit Plan, Actual Plan Asset Allocations		19.00%	19.00%
Liability Driven Investment Funds [Member]
Defined Benefit Plan, Fair Value of Plan Assets		$ 5,168	$ 3,615
Defined Benefit Plan, Actual Plan Asset Allocations		22.00%	17.00%
Defined Benefit Plan, Cash and Cash Equivalents [Member]
Defined Benefit Plan, Fair Value of Plan Assets		$ 1,860	$ 1,514
Defined Benefit Plan, Actual Plan Asset Allocations		8.00%	7.00%
Other Plan Assets [Member]
Defined Benefit Plan, Fair Value of Plan Assets		$ 246	$ 532
Defined Benefit Plan, Actual Plan Asset Allocations		1.00%	3.00%
[1]	Updated dimension from: "Debt Securities [Member]".

Note 8 - Employee Benefit Pl_11

Note 8 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan, Fair Value of Plan Assets	$ 23,926	$ 21,114	$ 17,819
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	1,860	1,514
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	22,066	19,600
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	$ 0	$ 0

Note 9 - Leases - Lease Expense

Note 9 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating lease cost	$ 2,153	$ 2,084
Short term lease cost	175	245
Sublease income	(183)	(429)
Total lease cost	$ 2,145	$ 1,900

Note 9 - Leases - Supplemental

Note 9 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:	$ 2,717	$ 2,530
Right-of-use assets obtained in exchange for lease obligations:	$ 455	$ 177

Note 9 - Leases - Supplementa_2

Note 9 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Operating lease right-of use assets	$ 7,761	$ 8,463
Current portion, operating lease liabilities	2,111	2,424
Operating lease liabilities, long term	7,481	8,224
Total operating lease liabilities	$ 9,592	$ 10,648
Weighted average remaining lease term (in years) (Year)	7 years 4 months 24 days	8 years 1 month 6 days
Weighted average discount rate	9.30%	9.20%

Note 9 - Leases - Future Minimu

Note 9 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
2021	$ 2,111
2022	2,018
2023	1,970
2024	1,715
2025	1,000
Thereafter	4,854
Total lease payments	13,668
Less interest	(4,076)
Total operating lease liabilities	$ 9,592	$ 10,648

Note 10 - Capital Stock and S_3

Note 10 - Capital Stock and Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Preferred Stock, Shares Authorized (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0
Employee Stock Purchase Plan, Consecutive Payment Periods (Year)	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date	85.00%
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan (in shares)	350,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)	126,255	190,642
Employee Stock Ownership Plan, Shares Available for Issuance (in shares)	192,341
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	2,975,717
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	5,010,931	4,386,063
Share Price (in dollars per share)	$ 4.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 92,162
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 4,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.21	$ 1.40
Preferred Stock, Shares Issued, Total (in shares)		0
Market Condition Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	332,622	605,005
Minimum Percentage Of Target, Number of Restricted Stock Units	0.00%
Maximum Vesting Rate of the Targeted Shareholder Return, Percentage	150.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Performance Factor Adjustment (in shares)	233,055
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 2.98	$ 1.98
In The Money Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)	862,149
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years

Note 10 - Capital Stock and S_4

Note 10 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Opening Balance, Stock Options Outstanding (in shares)	2,266,122	1,956,732
Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.93	$ 4.25
Options, Granted in Period (in shares)	894,154	943,424
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share)	$ 2.61	$ 3.28
Options, exercised (in shares)	(253,853)	(3,750)
Options, exercised, weighted average exercise price (in dollars per share)	$ 3.94	$ 2.98
Options, Cancelled / Forfeited in Period (in shares)	(269,084)	(630,284)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share)	$ 3.68	$ 3.96
Opening Balance, Stock Options Outstanding (in shares)	2,637,339	2,266,122
Options, Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.51	$ 3.93
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units Outstanding , Balance (in shares)	1,590,450	1,233,762
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 2.27	$ 3.36
Restricted Stock Units, Granted in Period (in shares)	1,027,486	1,652,720
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)	$ 2.75	$ 2.31
Restricted Stock Units, Vested in Period (in shares)	(930,985)	(813,762)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share)	$ 2.41	$ 3.29
Restricted Stock Units, Cancelled / Forfeited in Period (in shares)	(126,490)	(482,270)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)	$ 3.13	$ 3.42
Market Condition RSU - factor adjustment (in shares)	0
Market Condition RSU - factor adjustment (in dollars per share)	$ 0
Restricted Stock Units Outstanding , Balance (in shares)	1,560,461	1,590,450
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 2.44	$ 2.27
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares)	529,491	116,944
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 1.67	$ 4.19
Restricted Stock Units, Granted in Period (in shares)	332,622	605,005
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)	$ 2.98	$ 1.98
Restricted Stock Units, Vested in Period (in shares)	(240,205)	(3,778)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share)	$ 1.53	$ 4.19
Restricted Stock Units, Cancelled / Forfeited in Period (in shares)	(41,932)	(188,680)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)	$ 3.04	$ 4.18
Market Condition RSU - factor adjustment (in shares)	233,055
Market Condition RSU - factor adjustment (in dollars per share)	$ 1.47
Restricted Stock Units Outstanding , Balance (in shares)	813,031	529,491
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 2.12	$ 1.67

Note 10 - Capital Stock and S_5

Note 10 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Basic (in shares)	38,640,284	37,813,580
Dilutive effect of equity awards (in shares)	0	0
Diluted (in shares)	38,640,284	37,813,580

Note 10 - Capital Stock and S_6

Note 10 - Capital Stock and Stock-based Compensation - Outstanding and Exercisable Options (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Range of Exercise Price, Lower Limit (in dollars per share)	$ 1.78
Range of Exercise Price, Upper Limit (in dollars per share)	$ 5.63
Options Outstanding, Shares Outstanding (in shares) | shares	2,637,339
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	5 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.51
Options Outstanding, Aggregate Intrinsic Value | $	$ 2,493
Options Exercisable, Shares Exercisable (in shares) | shares	1,613,949
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 6 months
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.04
Options Exercisable, Aggregate Intrinsic Value | $	$ 849
Exercise Price Range 1 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 1.78
Range of Exercise Price, Upper Limit (in dollars per share)	$ 2.62
Options Outstanding, Shares Outstanding (in shares) | shares	357,018
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	7 years 6 months
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.27
Options Outstanding, Aggregate Intrinsic Value | $	$ 723
Options Exercisable, Shares Exercisable (in shares) | shares	96,488
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 9 months 18 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.29
Options Exercisable, Aggregate Intrinsic Value | $	$ 193
Exercise Price Range 2 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 2.63
Range of Exercise Price, Upper Limit (in dollars per share)	$ 2.66
Options Outstanding, Shares Outstanding (in shares) | shares	717,044
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 4 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.63
Options Outstanding, Aggregate Intrinsic Value | $	$ 1,190
Options Exercisable, Shares Exercisable (in shares) | shares	179,264
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	6 years 4 months 24 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.63
Options Exercisable, Aggregate Intrinsic Value | $	$ 298
Exercise Price Range 3 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 2.67
Range of Exercise Price, Upper Limit (in dollars per share)	$ 3.92
Options Outstanding, Shares Outstanding (in shares) | shares	568,784
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	7 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.33
Options Outstanding, Aggregate Intrinsic Value | $	$ 545
Options Exercisable, Shares Exercisable (in shares) | shares	348,704
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	6 years 2 months 12 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.36
Options Exercisable, Aggregate Intrinsic Value | $	$ 323
Exercise Price Range 4 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 3.93
Range of Exercise Price, Upper Limit (in dollars per share)	$ 4.38
Options Outstanding, Shares Outstanding (in shares) | shares	587,693
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	2 years 10 months 24 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.23
Options Outstanding, Aggregate Intrinsic Value | $	$ 35
Options Exercisable, Shares Exercisable (in shares) | shares	587,693
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	2 years 10 months 24 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.23
Options Exercisable, Aggregate Intrinsic Value | $	$ 35
Exercise Price Range 5 [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	$ 4.39
Range of Exercise Price, Upper Limit (in dollars per share)	$ 5.63
Options Outstanding, Shares Outstanding (in shares) | shares	406,800
Options Outstanding, Weighted Average Remaining Contractual Life (Year)	4 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 5.37
Options Outstanding, Aggregate Intrinsic Value | $	$ 0
Options Exercisable, Shares Exercisable (in shares) | shares	401,800
Options Exercisable. Weighted Average Remaining Contractual Life (Year)	4 years 3 months 18 days
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 5.38
Options Exercisable, Aggregate Intrinsic Value | $	$ 0

Note 10 - Capital Stock and S_7

Note 10 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based compensation	$ 3,647	$ 3,034
Continuing Operations [Member] | Cost of Sales [Member]
Share-based compensation	65	43
Continuing Operations [Member] | Selling and Marketing Expense [Member]
Share-based compensation	263	119
Continuing Operations [Member] | General and Administrative Expense [Member]
Share-based compensation	3,122	2,710
Continuing Operations [Member] | Research and Development Expense [Member]
Share-based compensation	$ 197	$ 162

Note 10 - Capital Stock and S_8

Note 10 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Volatility	58.30%	48.10%
Risk-free interest rate	0.30%	2.10%
Expected holding period (Year)	4 years 4 months 24 days	4 years 8 months 12 days
Dividend Yield	0.00%	0.00%

Note 10 - Capital Stock and S_9

Note 10 - Capital Stock and Stock-based Compensation - Monte Carlo Assumptions (Details) - Monte-Carlo Valuation Simulation [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Volatility	80.60%	59.00%
Risk-free interest rate	0.20%	2.00%
Correlation coefficient	31.50%	23.60%
Dividend Yield	0.00%	0.00%

Note 11 - Long Term Debt (Detai

Note 11 - Long Term Debt (Details Textual) - USD ($) $ in Thousands	Dec. 22, 2020	Apr. 18, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021	Jan. 31, 2018
Long-term Debt, Gross			$ 49,400
Debt Issuance Costs, Net, Total			1,393	$ 1,180
Repayments of Long-term Debt, Total			66,912	11,703
Payment for Debt Extinguishment or Debt Prepayment Cost			599	0
Write off of Deferred Debt Issuance Cost			787	0
Interest Rate Swap [Member] | PNC Bank [Member]
Payment for Debt Extinguishment or Debt Prepayment Cost			500
Derivative Asset, Notional Amount						$ 36,000
Derivative Asset, Notional Amount Of Instrument Cancelled			$ 23,000
London Interbank Offered Rate (LIBOR) [Member] | Interest Rate Swap [Member]
Derivative, Fixed Interest Rate						2.72%
Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End			3.25%
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total	$ 1,300
The Credit Agreement [Member] | Forecast [Member]
Debt Instrument, Quarterly Payment, Current Year					$ 500
Debt Instrument Quarterly Payment Next Eight Years					750
Debt Instrument, Quarterly Payment, Thereafter					$ 1,000
Percentage of Consolidated Excess Cash Flow					50.00%
The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage			0.50%
The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3.25%
The Credit Agreement [Member] | Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage			1.00%
The Credit Agreement [Member] | The ABR Loan [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
The Credit Agreement [Member] | The ABR Loan [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate			3.00%
The Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Remaining Borrowing Capacity			$ 15,600
The Prior Credit Facility [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 25,000
Repayments of Long-term Debt, Total	46,700
Payment for Debt Extinguishment or Debt Prepayment Cost	600
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 6,100
Term Loan [Member]
Long-term Debt, Gross			$ 40,000	$ 54,997
Term Loan [Member] | The Prior Credit Facility [Member]
Long-term Debt, Gross						$ 64,000
Term Loan [Member] | The Prior Credit Facility [Member] | Revolving Credit Facility [Member]
Write off of Deferred Debt Issuance Cost	800
The LIBOR Loan and Pricing Grid Credit Agreement [Member] | The Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			2.00%
The Lenders [Member] | The Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	10,000
The Lenders [Member] | The Credit Agreement [Member] | Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	10,000
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.25%
The Lenders [Member] | The Credit Agreement [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.50%
The Lenders [Member] | Term Loan [Member] | The Credit Agreement [Member]
Long-term Debt, Gross	40,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000

Note 11 - Long Term Debt - Brea

Note 11 - Long Term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Long-term debt, gross	$ 49,400
Less: unamortized deferred financing costs	(1,393)	$ (1,180)
Total debt	48,007	53,817
Less: current installments	(2,000)	(3,200)
Less: excess cash flow sweep	0	(4,093)
Current unamortized deferred financing costs	279	393
Long-term debt	46,286	46,917
Term Loan [Member]
Long-term debt, gross	40,000	54,997
Line of Credit [Member]
Long-term debt, gross	$ 9,400	$ 0

Note 11 - Long Term Debt - Debt

Note 11 - Long Term Debt - Debt Maturity (Details) $ in Millions	Dec. 31, 2020USD ($)
2021	$ 2
2022	3
2023	3
2024	4
2025	37.4
Total	$ 49.4

Note 11 - Long Term Debt - Deri

Note 11 - Long Term Debt - Derivative Instruments (Details) - Interest Rate Swap [Member] - Cash Flow Hedging [Member] - Other Noncurrent Liabilities [Member] $ in Thousands	Dec. 31, 2019USD ($)
Derivatives, notional amount	$ 28,821
Derivatives, fair value	$ (603)	[1]
[1]	See Note 12 for the fair value measurements related to these financial instruments.

Note 11 - Long Term Debt - Effe

Note 11 - Long Term Debt - Effect of Derivatives on AOCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Interest rate swaps	$ 206	$ 572
Interest rate swaps	809	139
Interest Rate Swap [Member] | Cash Flow Hedging [Member]
Interest rate swaps	(206)	(572)
Interest Rate Swap [Member] | Cash Flow Hedging [Member] | Interest Expense [Member]
Interest rate swaps	319	139
Interest Rate Swaps Settlement [Member] | Cash Flow Hedging [Member] | Debt Extinguishment and Related costs [Member]
Interest rate swaps	$ 490	$ 0

Note 12 - Fair Value Measurem_3

Note 12 - Fair Value Measurements (Details Textual) $ in Thousands	Dec. 31, 2020USD ($)
Interest Rate Swap [Member]
Derivative Liability, Total	$ 0

Note 12 - Fair Value Measurem_4

Note 12 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Interest Rate Swap [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative liabilities	$ 0
Fair Value, Recurring [Member]
Derivative liabilities		$ (603)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liabilities		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liabilities		(603)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liabilities		$ 0

Note 13 - Revenues - Disaggrega

Note 13 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 102,100	$ 116,176
Balance	3,949	3,820
Deferral of revenue	4,631	3,247
Recognition of deferred revenue	(4,820)	(3,127)
Effect of foreign currency translation	11	9
Balance	3,771	3,949
Service [Member]
Balance	1,587	1,659
Deferral of revenue	3,329	2,152
Recognition of deferred revenue	(3,298)	(2,233)
Effect of foreign currency translation	11	9
Balance	1,629	1,587
Customer Advances [Member]
Balance	2,362	2,161
Deferral of revenue	1,302	1,095
Recognition of deferred revenue	(1,522)	(894)
Effect of foreign currency translation	0	0
Balance	2,142	2,362
UNITED STATES
Revenues	102,100
UNITED STATES | Instruments, Equipment, Software, and Accessories [Member]
Revenues	97,473
UNITED STATES | Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 4,627
UNITED KINGDOM
Revenues		116,176
UNITED KINGDOM | Instruments, Equipment, Software, and Accessories [Member]
Revenues		110,220
UNITED KINGDOM | Service, Maintenance, and Warranty Contracts [Member]
Revenues		$ 5,956

Note 13 - Revenues - Allowance

Note 13 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance, beginning of period	$ 325	$ 332
Bad debt expense	17	288
Charge-offs and other recoveries	(124)	(293)
Effect of foreign currency translation	9	(2)
Balance, end of period	$ 227	$ 325

Note 13 - Revenues - Warranties

Note 13 - Revenues - Warranties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Warranty, Beginning Balance	$ 252	$ 391
Warranty Additions	77	10
Warranty (Payments) or Credits	(143)	(149)
Warranty, Ending Balance	$ 186	$ 252

Note 14 - Income Tax (Details T

Note 14 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Percent, Total	(7.10%)	14.80%
Deferred Tax Assets, Valuation Allowance, Total	$ 16,682	$ 13,745
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,900	(200)
Valuation Allowance, US Deferred Tax Assets and UK Pension Assets, Increase (Decrease), Amount	700
Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions	1,000
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	800
Deferred Tax Assets, Tax Credit Carryforwards, Total	3,200
Cash and Cash Equivalents in Foreign Subsidiaries	2,500	3,500
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities	39	398
Unrecognized Tax Benefits, Decrease Resulting from Acquisition		65
Unrecognized Tax Benefits, Increase Resulting from Audits		100
Unrecognized Tax Benefits, Increase Resulting from Credits	300
Unrecognized Tax Benefits, Increase Resulting from State Income Tax Issues	100
Decrease in Unrecognized Tax Benefits is Reasonably Possible	300
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,700
Tax Cuts and Jobs Act, Change in Tax Rate Operating Loss Carryforwards From Acquisition, CARES Act	5,300
Deferred Tax Assets, Valuation Allowance, Increase (Decrease) Due to Change in Tax Rate Operating Loss Carryforward From Acquisition CARES Act	1,100
Expire 2021 [Member]
Tax Credit Carryforward, Amount	200
Deferred Tax Assets, Tax Credit Carryforwards, Research	8,500
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	28,100
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expire Between 2021 and 2037 [Member]
Operating Loss Carryforwards, Total	22,800
State and Local Jurisdiction [Member]
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities		400
State and Local Jurisdiction [Member] | Expire between 2021 and 2040 [Member]
Operating Loss Carryforwards, Total	19,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	7,300
Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities		$ 100
Foreign Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 200

Note 14 - Income Tax - Income T

Note 14 - Income Tax - Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Federal and state	$ 169	$ (707)
Foreign	492	290
current income tax (benefit) expense	661	(417)
Federal and state	245	(281)
Foreign	(388)	(117)
deferred income tax (benefit) expense	(143)	(398)
Total income tax expense (benefit), amount	$ 518	$ (815)

Note 14 - Income Tax - Income_2

Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Computed "expected" income tax benefit, amount	$ (1,531)	$ (1,161)
Computed "expected" income tax benefit, percent	21.00%	21.00%
Permanent differences, net, amount	$ 141	$ 241
Permanent differences, net, percent	(1.90%)	(4.40%)
Foreign tax rate differential, amount	$ (14)	$ 42
Foreign tax rate differential, percent	0.20%	(0.80%)
State income taxes, net of federal income tax benefit, amount	$ (77)	$ (74)
State income taxes, net of federal income tax benefit, percent	1.10%	1.30%
Non-deductible stock compensation expense, amount	$ 94	$ 205
Non-deductible stock compensation expense, percent	(1.30%)	(3.70%)
Tax credits, amount	$ (192)	$ (220)
Tax credits, percent	2.60%	(4.00%)
Tax credits, amount	$ 192	$ 220
Change in reserve for uncertain tax position, amount	$ 259	$ (111)
Change in reserve for uncertain tax position, percent	(3.60%)	2.00%
Impact of change to prior year tax accruals, amount	$ 168	$ 314
Impact of change to prior year tax accruals, percent	(2.30%)	(5.70%)
Change in valuation allowance allocated to income tax, amount	$ 2,130	$ (578)
Change in valuation allowance allocated to income tax, percent	(29.20%)	10.50%
Other, amount	$ (460)	$ 87
Other, percent	6.30%	(1.40%)
Total income tax expense (benefit), amount	$ 518	$ (815)
Total income tax expense (benefit), percent	(7.10%)	14.80%

Note 14 - Income Tax - Pre-tax

Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Domestic	$ (7,954)	$ (5,616)
Foreign	662	114
Loss before income taxes	$ (7,292)	$ (5,502)

Note 14 - Income Tax - Deferred

Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory	$ 1,144	$ 1,079
Operating loss and credit carryforwards	19,220	18,802
Accrued expenses	555	654
Deferred interest expense	1,476	1,475
Stock compensation	1,079	1,011
Lease liability	1,823	2,081
Other assets	458	223
Total gross deferred assets	25,755	25,325
Less: valuation allowance	(16,682)	(13,745)
Deferred tax assets:	9,073	11,580
Indefinite-lived intangible assets	1,822	2,048
Definite-lived intangible assets	7,493	9,168
Right-of-use asset	1,388	1,580
Other Liabilities	14	507
Total deferred tax liabilities	10,717	13,303
Deferred income tax liability, net	(1,644)	(1,723)
Deferred tax assets (included in other long-term assets)	255	251
Deferred income tax liabilities	$ (1,899)	$ (1,974)

Note 14 - Income Tax - Unrecogn

Note 14 - Income Tax - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance	$ 1,353	$ 1,860
Additions based on tax positions of prior years	157	68
Decreases based on tax positions of prior years	(11)	(133)
Additions based on tax positions of current years	213	21
Settlements	(39)	(398)
Decreases based on tax positions of acquired entities		(65)
Balance	$ 1,673	$ 1,353

Note 16 - Segment and Related_3

Note 16 - Segment and Related Information (Details Textual)	12 Months Ended
	Dec. 31, 2020
Number of Operating Segments	1

Note 16 - Segment and Related_4

Note 16 - Segment and Related Information - Revenue From External Customers by Geographic Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total revenues	$ 102,100	$ 116,176
UNITED STATES
Total revenues	102,100
Continuing Operations [Member]
Total revenues	102,100	116,176
Continuing Operations [Member] | UNITED STATES
Total revenues	42,054	47,792
Continuing Operations [Member] | Europe [Member]
Total revenues	29,938	35,128
Continuing Operations [Member] | Asia [Member]
Total revenues	23,884	25,041
Continuing Operations [Member] | Rest of the World [Member]
Total revenues	$ 6,224	$ 8,215

Note 16 - Segment and Related_5

Note 16 - Segment and Related Information - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Total long-lived assets	[1]	$ 44,618	$ 50,509
UNITED STATES | Continuing Operations [Member]
Total long-lived assets		36,568	41,993
GERMANY | Continuing Operations [Member]
Total long-lived assets		4,958	5,468
Rest of the World [Member] | Continuing Operations [Member]
Total long-lived assets		$ 3,092	$ 3,048
[1]	consists of operating lease right-of-use assets, property, plant and equipment, net and amortizable intangible assets, net.

Note 16 - Segment and Related_6

Note 16 - Segment and Related Information - Net Assets by Geographic Area (Details) - Continuing Operations [Member] - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Total net assets	$ 76,681	$ 81,694
UNITED STATES
Total net assets	32,457	37,726
GERMANY
Total net assets	18,697	17,340
UNITED KINGDOM
Total net assets	8,867	11,254
Rest of the World [Member]
Total net assets	$ 16,660	$ 15,374